Expert Stephen Oh, MD, PhD, provides a broad overview of the myeloproliferative neoplasms: polycythemia vera, essential thrombocythemia, and myelofibrosis.

Shared insight on making a differential diagnosis of polycythemia vera and properly risk-stratifying patients who present with this disease.

Pankit Vachhani, MD, provides a comprehensive overview of approved agents used to manage patients with polycythemia vera.

A brief discussion on the role of ruxolitinib in the management of polycythemia vera, followed by a review of goals of therapy in this setting.

Shared insight on the differential diagnosis of myelofibrosis, including advice for identifying primary versus secondary disease.

Reflections on the predominant challenges one may face while making a differential diagnosis of myelofibrosis.

Experts focus on how best to risk stratify and stage myelofibrosis using appropriate diagnostic tools and workup.

Expert Pankit Vachhani, MD, breaks down best practices in observation and dictates when it is best to initiated therapy for myelofibrosis.

Stephen Oh, MD, PhD, highlights the role of transplant in myelofibrosis before Ruben Mesa, MD, discusses factors in selecting systemic therapy.

A brief review of the historical use of systemic therapy in patients who present with myelofibrosis.

Expert perspectives on the role of ruxolitinib in patients who require systemic therapy for myelofibrosis.

Shared insight on the respective roles of fedratinib and pacritinib in patients diagnosed with myelofibrosis.

Taking into account the three JAK inhibitors, ruxolitinib, fedratinib, and pacritinib, experts reflect on the appropriate use of each agent in myelofibrosis.

Expert perspectives on monitoring patients receiving therapy for myelofibrosis, with additional considerations for when it is appropriate to switch therapy.

A comprehensive review of novel agents currently under investigation with a potential role in the myelofibrosis treatment landscape.

Focusing on novel combination strategies, experts review clinical trial data and consider where these regimens may fall in the myelofibrosis treatment armamentarium.

Closing out their discussion on myelofibrosis, experts provide practical advice for identifying and managing patients in real-world practice.